Engineering next generation cancer immuno-therapeutics: effective cancer killing and preventing recurrence
TollCyto Therapeutics
A precision-engineered oncolytic virus platform - starting with non-muscle invasive bladder cancer.
HSV5-15 is built to kill tumour cells locally and train durable protective immunity in the bladder lining. Explore the science, the pipeline, and the team behind it.
Science
How HSV5-15 works
An HSV-1 backbone, disarmed by two precise gene deletions and armed with a TLR5 agonist and cytokine payload.
Explore the sciencePipeline
Programmes & indications
Lead programme in NMIBC, with discovery-stage assets in prostate, breast and sarcoma.
See the pipelineAbout
The team
A biotech spin-out with deep virology, immunology and clinical expertise, backed by leading academic partners.
Meet the team